Shell Asset Management’s PDL BioPharma, Inc. PDLI Stock Holding History

Shell Asset Management’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-62,163	Closed	-$195K	–	1284
2019 Q2	$195K	Sell	62,163 -72,845	-54%	-$236K	﹤0.01%	1127
2019 Q1	$502K	Hold	135,008	–	–	0.01%	909
2018 Q4	$392K	Sell	135,008 -11,400	-8%	-$31.3K	0.01%	921
2018 Q3	$385K	Hold	146,408	–	–	0.01%	1025
2018 Q2	$343K	Sell	146,408 -8,258	-5%	-$23.1K	0.01%	1006
2018 Q1	$455K	Hold	154,666	–	–	0.01%	935
2017 Q4	$424K	Hold	154,666	–	–	0.01%	950
2017 Q3	$524K	Sell	154,666 -3,600	-2%	-$10K	0.01%	858
2017 Q2	$391K	Hold	158,266	–	–	0.01%	953
2017 Q1	$359K	Sell	158,266 -11,076	-7%	-$24.5K	0.01%	974
2016 Q4	$359K	Sell	169,342 -1,480	-0.9%	-$4.13K	0.01%	952
2016 Q3	$572K	Buy	+170,822	New	+$542K	0.01%	815
2015 Q4	–	Sell	-242,091	Closed	-$1.81M	–	1006
2015 Q3	$1.81M	Buy	+242,091	New	+$1.39M	0.03%	507
2014 Q4	–	Sell	-242,091	Closed	-$1.81M	–	907
2014 Q3	$1.81M	Buy	+242,091	New	+$2.25M	0.03%	521

Other funds holding PDLI

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Shell Asset Management's PDLI Position: Q3 2019 in Review

Shell Asset Management sold out of PDL BioPharma, Inc. (PDLI) in Q3 2019, closing a stake of 62,163 shares — an estimated $195K sold.

Shell Asset Management first reported a position in PDLI in Q3 2014 and held it in 14 quarters. The position peaked at $1.81M in Q3 2015. 140 funds tracked by Wall St. Rank hold PDLI as of Q3 2019.

Shell Asset Management reported no remaining PDL BioPharma, Inc. position as of Q3 2019 after selling out during the quarter.
Shell Asset Management sold 62,163 PDL BioPharma, Inc. shares in Q3 2019, an estimated $195K.
Shell Asset Management first reported a position in PDL BioPharma, Inc. in Q3 2014 and held it in 14 quarters.
Shell Asset Management's PDL BioPharma, Inc. position peaked at $1.81M in Q3 2015.
140 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q3 2019.

Based on Shell Asset Management's 13F filing for Q3 2019, filed 12 Nov 2019.